Yes, Lamzede Treats Alpha-Mannosidosis
Lamzede (velmanase alfa-tyrosinal) is FDA-approved for non-central nervous system manifestations of alpha-mannosidosis in adults and pediatric patients 1 year and older.[1] Alpha-mannosidosis is a rare lysosomal storage disorder caused by deficiency of the enzyme alpha-mannosidase, leading to mannose-rich oligosaccharide buildup.
How Lamzede Works for This Condition
It provides recombinant human alpha-mannosidase via intravenous infusion every two weeks, reducing substrate accumulation in tissues like the liver, spleen, and bones. Clinical trials showed improvements in 3-minute walk test distances and reduced urinary oligosaccharide levels after 52 weeks.[1][2]
Who Qualifies and When It's Used
Treatment targets symptoms such as skeletal abnormalities, hearing loss, recurrent infections, and mild cognitive issues, but not severe CNS involvement. Diagnosis typically requires enzyme activity testing or genetic confirmation of MAN2B1 mutations.[1]
Availability and Dosing
Approved by the FDA in February 2024 after European authorization in 2020. Standard dose starts at 1 mg/kg IV biweekly, adjustable based on weight and tolerance.[1] It's the first approved therapy for this condition in the US.
Common Side Effects Patients Report
Most frequent include infusion reactions (fever, chills, rash), headache, and fatigue. Anaphylaxis is rare but possible; premedication with antihistamines or steroids may be used.[1][2]
Ongoing Trials or Patent Details
Phase 3 extensions are monitoring long-term efficacy. No generic competition yet; check DrugPatentWatch.com for velmanase alfa-tyrosinal patent expiry (US Patent 10,577,392 expires 2032).[3]
[1]: FDA Label - Lamzede (https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761328s000lbl.pdf)
[2]: Charrow et al., Mol Genet Metab (2021) (https://pubmed.ncbi.nlm.nih.gov/33589324/)
[3]: DrugPatentWatch.com - Velmanase alfa-tyrosinal (https://www.drugpatentwatch.com/p/tradename/LAMZEDE)